Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure - Full Text View

Sponsored by:	Clayton Sleep Insititute
Information provided by:	Clayton Sleep Insititute
ClinicalTrials.gov Identifier:	NCT00665977

Purpose

CPAP compliance will be significantly higher in both the heated humidity with Thermosmart™ and the nasal steroid phases compared to the double placebo phase.
CPAP compliance will be comparably improved in the heated humidity with Thermosmart™ phase versus the nasal steroid phase.
Improvement in nasal symptoms in using CPAP will be significantly improved in both the heated humidity with Thermosmart™ and the nasal steroid phases compared to the double placebo phase, and comparable between the heated humidity with Thermosmart™ phase versus the nasal steroid phase.
Secondary to improvements in CPAP compliance, measures of daytime functioning and quality of life will improve in the heated humidity with Thermosmart™ versus double placebo.

Condition	Intervention	Phase
Obstructive Sleep Apnea Nasal Congestion Sinus Congestion	Drug: Thermosmart & placebo Drug: Placebo Device & Nasacort Device: Placebo Arm	Phase III

MedlinePlus related topics: Sleep Apnea

Drug Information available for: Triamcinolone diacetate Triamcinolone acetonide Triamcinolone Triamcinolone hexacetonide

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study
Official Title:	Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure

Further study details as provided by Clayton Sleep Insititute:

Primary Outcome Measures:

Although an exact & universal definition of CPAP compliance has not been determined. Compliance will be tracked by the CPAP unit and downloaded into an analysis program for review at each visit. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Nasal Symptom Assessment, Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire, PSQI, Clayton Daytime Fatigue Scale, ESS, FSS, FOSQ, Actigraphy, Sleep, and Diary/Daily Assessments [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	44
Study Start Date:	September 2007
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Sham Comparator To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and "deactivated" Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still "appear" to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily.	Device: Placebo Arm To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and "deactivated" Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still "appear" to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily.
Double Blind Treatment Group 2: Active Comparator Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.	Drug: Placebo Device & Nasacort Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
Double Blind Treatment Goup 1: Active Comparator a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily	Drug: Thermosmart & placebo a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily

Detailed Description:

Eligible participants will undergo this double-blind, placebo controlled, single-blind double placebo run-in, crossover trial to determine the efficacy of heated humidity with Thermosmart™ in improving compliance and nasal symptoms in patients using CPAP versus a nasal steroid and placebo (heated humidity, nasal steroid placebo) phases. After successful screening, participants will undergo a two week single-blind double placebo run-in phase using heated humidity and a nasal steroid placebo. The double-blind treatment phase will last a total of six weeks. Participants will undergo both phases: three weeks using heated humidity with Thermosmart™ and nasal steroid placebo and three weeks using a nasal steroid with a heated humidifier. Treatment phases will be counterbalanced. Study participation will last a total of 8 weeks from screening to completion of double-blind treatment.

Eligibility

Ages Eligible for Study:	16 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Between the ages of 18-65
Diagnosis of obstructive sleep apnea (OSA) with apnea/hypopnea index (AHI) > 15/hr
Currently using CPAP therapy and within 3 weeks to 12 months of initial CPAP titration
Based on the CPAP nasal symptom questionnaire, a score of at least 3 (sometimes) for at least one of the following nasal symptoms related to their sleep apnea and CPAP usage: nasal congestion, runny nose, sneezing, or nasal irritation
Willingness to tolerate and continue therapy with nCPAP
Successfully titrated on nCPAP in a sleep center to a pressure between 6-16 cmH2O
Willingness to comply and complete study related procedures
Fluent in the English language

Exclusion Criteria:

Co-morbid medical condition that is either medically significant and unstable, would interfere with the patient's ability to routinely use CPAP, or is a contraindication for use of a nasal steroid
Women who are pregnant or who may potentially become pregnant during the course of the research trial.
CPAP compliance over the past three weeks at screening > 5 hours/night, suggesting no compromised CPAP usage due to adverse nasal symptoms
Wake resting SaO2 < 90%
Currently using Bi-Level therapy, supplemental oxygen with CPAP therapy, or using a pressure outside inclusion criteria
Currently using a Full-Face mask for CPAP therapy
Current or prior use of the Fisher Paykel 604 CPAP machine with Thermosmart™ heated humidity.
Patients who were never prescribed a heated humidifier with their CPAP machine (i.e. no humidifier or passover humidifier).
Intranasal steroid treatment within the previous six months. Patient's currently taking intranasal steroid treatment cannot wash-out of steroid treatment to be included nor if patients have used nasal steroid treatment while on CPAP therapy
Current upper airway tract infection, influenza, respiratory infection at time of screening or nasal surgery within 90 days of screening
Prior surgical intervention for obstructive sleep apnea
Currently taking medications that would be contraindicated to using a nasal steroid. Patients taking hypnotic or wake promoting therapy can participate if they have been on a stable dose prior to CPAP therapy and willing to maintain current dose as prescribed.
Shift or rotating shift workers or individuals who routinely cannot contribute at least 6 hours/night to sleep/attempting therapy
Additional sleep disorder that would interfere with routine use of CPAP

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00665977

Contacts

Contact: Krista Russell, CCRC	314-645-6005	research@claytonsleep.com
Contact: Research Coordinator	314-645-6005	research@claytonsleep.com

Locations

United States, Missouri
Clayton Sleep Institute	Recruiting
St. Louis, Missouri, United States, 63143
Contact: Research Coordinator 314-645-6605 research@claytonsleep.com
Principal Investigator: Eric D Powell, PhD

Sponsors and Collaborators

Clayton Sleep Insititute

More Information

No publications provided

Responsible Party:	Clayton Sleep Institute, LLC ( Eric Powell, PhD )
Study ID Numbers:	F & P 07-004
Study First Received:	February 7, 2008
Last Updated:	April 22, 2008
ClinicalTrials.gov Identifier:	NCT00665977 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Clayton Sleep Insititute:

Obstructive Sleep Apnea
Nasal Congestion
Sinus congestion

Study placed in the following topic categories:

Sleep Apnea Syndromes
Triamcinolone Acetonide
Respiratory Tract Diseases
Apnea
Triamcinolone
Respiration Disorders

Sleep Apnea, Obstructive
Dyssomnias
Sleep Disorders
Triamcinolone diacetate
Triamcinolone hexacetonide
Sleep Disorders, Intrinsic

Additional relevant MeSH terms:

Sleep Apnea Syndromes
Respiratory Tract Diseases
Apnea
Nervous System Diseases
Respiration Disorders

Sleep Apnea, Obstructive
Sleep Disorders
Dyssomnias
Sleep Disorders, Intrinsic

ClinicalTrials.gov processed this record on May 07, 2009